The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
Open accessAbstract
Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx‐markers into routine care, because the evidence base is currently limited to specific, individual drug‐gene pairs. The Ubiquitous Pharmacogenomics (U‐PGx) Consortium, which has been funded by the European Commission's Horizon‐2020 program, aims to address this unmet need. In a prospective, block‐randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre‐emptive genotyping of a panel of clinically relevant PGx‐markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost‐effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi‐ethnic, and multihealthcare system approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Self-citationHicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Self-citationPharmacogenomics in the clinic
Relling, M. V., & Evans, W. E. (2015) · Nature · doi:10.1038/nature15817 · Cited by 904
Charting a course for genomic medicine from base pairs to bedside
National Human Genome Research Institute, Green, E. D., & Guyer, M. S. (2011) · Nature · doi:10.1038/nature09764 · Cited by 902
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
Self-citationBirdwell, K., Decker, B., Barbarino, J., Peterson, J., Stein, C., Sadee, W., Wang, D., Vinks, A., He, Y., Swen, J., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.113 · Cited by 730
Self-citationCarbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009717 · Cited by 711
Cited by
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
Self-citationA Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Self-citationVolpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A., Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod, H. L., Roden, D. M., Williams, M. S., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1048 · Cited by 135
Polypharmacy and precision medicine
Fujita, K., Masnoon, N., Mach, J., O’Donnell, L. K., & Hilmer, S. N. (2023) · Cambridge Prisms: Precision Medicine · doi:10.1017/pcm.2023.10 · Cited by 27
Metadata
- Authors
- van der Wouden, C., Cambon‐Thomsen, A., Cecchin, E., Cheung, K., Dávila‐Fajardo, C., Deneer, V., Dolžan, V, Ingelman‐Sundberg, M., Jönsson, S., Karlsson, M., Kriek, M., Mitropoulou, C., Patrinos, G., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J., Sunder‐Plassmann, G., Toffoli, G., Turner, R., van Rhenen, M., Swen, J., Guchelaar, H., & on behalf of the Ubiquitous Pharmacogenomics Consortium
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-02-13
- Volume
- 101
- Issue
- 3
- Pages
- 341-358
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2562052809
- Cited by
- 306
- References
- 62
- FWCI
- 34.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. https://app.cochat.ai/papers/10.1002/cpt.602
- The paper
- van der Wouden, C., Cambon‐Thomsen, A., Cecchin, E., Cheung, K., Dávila‐Fajardo, C., Deneer, V., Dolžan, V, Ingelman‐Sundberg, M., Jönsson, S., Karlsson, M., Kriek, M., Mitropoulou, C., Patrinos, G., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J., . . . on behalf of the Ubiquitous Pharmacogenomics Consortium. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.